150 related articles for article (PubMed ID: 30400036)
21. AS1907417, a novel GPR119 agonist, as an insulinotropic and β-cell preservative agent for the treatment of type 2 diabetes.
Yoshida S; Tanaka H; Oshima H; Yamazaki T; Yonetoku Y; Ohishi T; Matsui T; Shibasaki M
Biochem Biophys Res Commun; 2010 Oct; 400(4):745-51. PubMed ID: 20816753
[TBL] [Abstract][Full Text] [Related]
22. Suppression of free fatty acid receptor 1 expression in pancreatic β-cells in obese type 2 diabetic db/db mice: a potential role of pancreatic and duodenal homeobox factor 1.
Kohara K; Obata A; Kimura T; Shimoda M; Moriuchi S; Okauchi S; Hirukawa H; Mune T; Kaku K; Kaneto H
Endocr J; 2019 Jan; 66(1):43-50. PubMed ID: 30333365
[TBL] [Abstract][Full Text] [Related]
23. Design, synthesis, and biological evaluations of phenylpropiolic acid derivatives as novel GPR40 agonists.
Jiang XW; Jiang BE; Liu H; Liu ZT; Hu LL; Liu M; Lu W; Zhang HK
Eur J Med Chem; 2018 Oct; 158():123-133. PubMed ID: 30212763
[TBL] [Abstract][Full Text] [Related]
24. The fatty acid receptor FFA1/GPR40 a decade later: how much do we know?
Mancini AD; Poitout V
Trends Endocrinol Metab; 2013 Aug; 24(8):398-407. PubMed ID: 23631851
[TBL] [Abstract][Full Text] [Related]
25. Design, synthesis and biological evaluation of vincamine derivatives as potential pancreatic β-cells protective agents for the treatment of type 2 diabetes mellitus.
Wang J; Lv X; Xu J; Liu X; Du T; Sun G; Chen J; Shen X; Wang J; Hu L
Eur J Med Chem; 2020 Feb; 188():111976. PubMed ID: 31918073
[TBL] [Abstract][Full Text] [Related]
26. Activation of GPR40 attenuates chronic inflammation induced impact on pancreatic β-cells health and function.
Verma MK; Sadasivuni MK; Yateesh AN; Neelima K; Mrudula S; Reddy M; Smitha R; Biswas S; Chandravanshi B; Pallavi PM; Oommen AM; Jagannath MR; Somesh BB
BMC Cell Biol; 2014 Jun; 15():24. PubMed ID: 24974801
[TBL] [Abstract][Full Text] [Related]
27. Novel GPR119 agonist HD0471042 attenuated type 2 diabetes mellitus.
Ha TY; Kim YS; Kim CH; Choi HS; Yang J; Park SH; Kim DH; Rhee JK
Arch Pharm Res; 2014 May; 37(5):671-8. PubMed ID: 23897163
[TBL] [Abstract][Full Text] [Related]
28. Modulating GPR40: therapeutic promise and potential in diabetes.
Poitout V; Lin DC
Drug Discov Today; 2013 Dec; 18(23-24):1301-8. PubMed ID: 24051395
[TBL] [Abstract][Full Text] [Related]
29. 20-HETE promotes glucose-stimulated insulin secretion in an autocrine manner through FFAR1.
Tunaru S; Bonnavion R; Brandenburger I; Preussner J; Thomas D; Scholich K; Offermanns S
Nat Commun; 2018 Jan; 9(1):177. PubMed ID: 29330456
[TBL] [Abstract][Full Text] [Related]
30. A Single Amino Acid Mutation (R104P) in the E/DRY Motif of GPR40 Impairs Receptor Function.
Guo S; Zhang J; Zhang S; Li J
PLoS One; 2015; 10(10):e0141303. PubMed ID: 26505901
[TBL] [Abstract][Full Text] [Related]
31. Structure-Activity Relationship Study and Biological Evaluation of 2-(Disubstituted phenyl)-indole-5-propanoic Acid Derivatives as GPR40 Full Agonists.
Zhao X; Yoon DO; Yoo J; Park HJ
J Med Chem; 2021 Apr; 64(7):4130-4149. PubMed ID: 33769827
[TBL] [Abstract][Full Text] [Related]
32. The relationship between GPR40 and lipotoxicity of the pancreatic β-cells as well as the effect of pioglitazone.
Wu P; Yang L; Shen X
Biochem Biophys Res Commun; 2010 Dec; 403(1):36-9. PubMed ID: 21036144
[TBL] [Abstract][Full Text] [Related]
33. Circulating LncRNAs Analysis in Patients with Type 2 Diabetes Reveals Novel Genes Influencing Glucose Metabolism and Islet β-Cell Function.
Ruan Y; Lin N; Ma Q; Chen R; Zhang Z; Wen W; Chen H; Sun J
Cell Physiol Biochem; 2018; 46(1):335-350. PubMed ID: 29590649
[TBL] [Abstract][Full Text] [Related]
34. Niacin receptor GPR109A inhibits insulin secretion and is down-regulated in type 2 diabetic islet beta-cells.
Wang N; Guo DY; Tian X; Lin HP; Li YP; Chen SJ; Fu YC; Xu WC; Wei CJ
Gen Comp Endocrinol; 2016 Oct; 237():98-108. PubMed ID: 27570060
[TBL] [Abstract][Full Text] [Related]
35. A new synthetic dual agonist of GPR120/GPR40 induces GLP-1 secretion and improves glucose homeostasis in mice.
Bianchini G; Nigro C; Sirico A; Novelli R; Prevenzano I; Miele C; Beguinot F; Aramini A
Biomed Pharmacother; 2021 Jul; 139():111613. PubMed ID: 33895521
[TBL] [Abstract][Full Text] [Related]
36. Chlorogenic acid and β-glucan from highland barley grain ameliorate β-cell dysfunction
Liu ZH; Li B
Food Funct; 2021 Oct; 12(20):10040-10052. PubMed ID: 34515712
[TBL] [Abstract][Full Text] [Related]
37. Activation of extracellular signal-regulated protein kinases 1 and 2 (ERK1/2) by free fatty acid receptor 1 (FFAR1/GPR40) protects from palmitate-induced beta cell death, but plays no role in insulin secretion.
Panse M; Gerst F; Kaiser G; Teutsch CA; Dölker R; Wagner R; Häring HU; Ullrich S
Cell Physiol Biochem; 2015; 35(4):1537-45. PubMed ID: 25792236
[TBL] [Abstract][Full Text] [Related]
38. Insulin sensitization via partial agonism of PPARγ and glucose uptake through translocation and activation of GLUT4 in PI3K/p-Akt signaling pathway by embelin in type 2 diabetic rats.
Gandhi GR; Stalin A; Balakrishna K; Ignacimuthu S; Paulraj MG; Vishal R
Biochim Biophys Acta; 2013 Jan; 1830(1):2243-55. PubMed ID: 23104384
[TBL] [Abstract][Full Text] [Related]
39. Epicatechin potentiation of glucose-stimulated insulin secretion in INS-1 cells is not dependent on its antioxidant activity.
Yang K; Chan CB
Acta Pharmacol Sin; 2018 May; 39(5):893-902. PubMed ID: 29417944
[TBL] [Abstract][Full Text] [Related]
40. GPR40 agonists for the treatment of type 2 diabetes mellitus: The biological characteristics and the chemical space.
Chen C; Li H; Long YQ
Bioorg Med Chem Lett; 2016 Dec; 26(23):5603-5612. PubMed ID: 27825762
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
